Interestingly, one study evaluated CD48 together with PD-L1, an immune checkpoint mechanism in glioma, suggesting that these two upregulated signaling pathways with anti-Aβ antibody exposure may trigger acute immunomodulatory response first (Zou et al., 2019). This evidence concerns the gene CD48 and central nervous system cancer.